Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0001507650-26-000003

Options or other derivatives

  • Co-Chief Executive Officer acquired 11,232 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Zanganeh Mahkam · Co-Chief Executive Officer

Table II: Derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-01-02 Grant or award : show line 1 in the form Stock Option (right to buy) +11,232 $8.76 $98,392 11,232 I
Loading xslF345X05/wk-form4_1767747171.xml…